CALT Company Profile and Key Details

Q: Who are the executives of CALT?

Mr. Mikael WidellHead of Communications & IRMr. Jonathan A. SchurGroup Gen. CounselMs. Sandra FrithiofHead of HRMs. Teona JohnsonHead of US MarketingMs. Renee Aguiar-LucanderChief Executive OfficerDr. Katayoun Welin-Berger Ph.D.Vice President of OperationsDr. Johan Haggblad Ph.D.Chief Scientific OfficerMr. Andrew B. Udell B.Sc., M.B.A.Pres of North America CommercialDr. Richard S. Philipson M.D.Chief Medical OfficerDr. Krassimir MitchevHead of Medical AffairsMr. Fredrik JohanssonChief Financial OfficerMs. Ann-Kristin Myde BScHead of Clinical Devel. & Vice President of Project Management

NASDAQ : CALT

Calliditas Therapeutics AB (publ)

$40.00

-0.0399-0.10%

At Close 4:00 PM

Not Actively Trading

62.66

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Calliditas Therapeutics AB (publ) (CALT) stock declined over -0.10%, trading at $40.00 on NASDAQ, down from the previous close of $40.04. The stock opened at $40.00, fluctuating between $40.00 and $43.00 in the recent session.

Stock Snapshot

40.04

Prev. Close

2.15B

Market Cap

Day Low

-22.727329545454545

P/E Ratio

-1.76

EPS (TTM)

-8.1

Cash Flow per Share

Open

53.69M

Number of Shares

Day High

2.5%

Free Float in %

6.24

Book Value

9.8K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 27, 2024	40.00	40.00	40.00	40.00	0
Sep 26, 2024	40.00	40.00	40.00	40.00	0
Sep 25, 2024	40.00	40.00	40.00	40.00	0
Sep 24, 2024	40.00	40.00	40.00	40.00	0
Sep 23, 2024	40.00	40.00	40.00	40.00	0
Sep 20, 2024	40.00	43.00	40.00	40.00	9.8K
Sep 19, 2024	40.40	40.55	40.07	40.16	5.1K
Sep 18, 2024	40.46	40.80	39.20	40.03	6.04K
Sep 17, 2024	40.34	40.34	39.99	39.99	1K
Sep 16, 2024	40.37	40.75	40.00	40.75	3.1K
Sep 13, 2024	39.90	40.30	39.04	40.00	4.32K
Sep 12, 2024	39.80	39.80	39.80	39.80	600
Sep 11, 2024	39.81	40.28	39.80	39.80	3.4K
Sep 10, 2024	39.79	40.07	39.78	39.78	1.34K
Sep 09, 2024	40.12	40.28	39.71	39.78	10.61K
Sep 06, 2024	40.00	41.31	40.00	40.75	22.7K
Sep 05, 2024	40.45	40.50	39.68	40.28	9.71K
Sep 04, 2024	41.14	41.50	39.71	40.45	18.13K
Sep 03, 2024	40.32	42.10	40.11	41.55	11.81K
Aug 30, 2024	40.12	40.14	39.69	40.12	4.42K

Contact Details

Stockholm, 111 22

Sweden

https://www.calliditas.se 468 411 3005

About Company

Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.

Stock Peers

ARGX

-4.96-0.57%

argenx SE$857.97 REGN

14.49+2.18%

Regeneron Pharmaceuticals, Inc.$678.94 MDGL

-4.72-0.86%

Madrigal Pharmaceuticals, Inc.$545.53 UTHR

-2.74-0.52%

United Therapeutics Corporation$529.05 VRTX

8.95+1.88%

Vertex Pharmaceuticals Incorporated$486.03 KRYS

-8.45-2.41%

Krystal Biotech, Inc.$341.79 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

6.16+1.98%

BeOne Medicines AG$317.42 PRAX

-10.22-3.21%

Praxis Precision Medicines, Inc.$308.20 LGND

0.19+0.06%

Ligand Pharmaceuticals Incorporated$296.45

Company Overview

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) closed at $40.00 USD, losing -$0.04 (-0.10%) from the previous close of $40.04. The stock is currently mid-range between its 52-week high and low $15.25 and $43.00. With a market capitalization of about $2.15 billion, Calliditas Therapeutics AB (publ) is classified as a mid-cap and shows higher-than-market volatility (beta ~1.46). Key stats such as the average daily volume over the past year has been around 7.73 thousand shares, in line with its 52-week average. Headquartered in Stockholm, None, Calliditas Therapeutics AB (publ) operates in the Healthcare sector and the Biotechnology industry. Led by CEO Renee Aguiar-Lucander, the company employs approximately 222 people and listed since June 05, 2020. Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -0.76%, SMA50 1.28%, SMA200 39.49%). The stock’s 14-day RSI is 50.49 (neutral), while the ATR of 1.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.98% below its high and over 162.3% above its low.

Valuation Metrics

Calliditas Therapeutics AB (publ) trades at a P/E ratio of -22.22, slightly below the S&P 500 average, with a price-to-sales ratio of 17.18 and a price-to-book ratio of 30.95 reflecting a rich premium to book value. The P/FCF stands at -46.34, also below market averages. Compared to sector medians, Calliditas Therapeutics AB (publ) P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Calliditas Therapeutics AB (publ) generated EPS of -$1.69 over the past year. Five-year average earnings growth is -22.85%. The latest quarter delivered EPS of -$0.58. The next quarter is forecast at $0.15. Next year's EPS is expected at $254.98. Calliditas Therapeutics AB (publ) earnings surprise history is a mixed track record. The quarter that ended November 11, 2024, missed forecasts by 163.64%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include 163.64% in November 07, 2023.

Frequently Asked Questions

What is the current Calliditas Therapeutics AB (publ) (CALT) stock price?

Calliditas Therapeutics AB (publ) (NASDAQ: CALT) stock price is $40.00 in the last trading session. During the trading session, CALT stock reached the peak price of $43.00 while $40.00 was the lowest point it dropped to. The percentage change in CALT stock occurred in the recent session was -0.1% while the dollar amount for the price change in CALT stock was - $0.04.

CALT's industry and sector of operation?

The NASDAQ listed CALT is part of Biotechnology industry that operates in the broader Healthcare sector. Calliditas Therapeutics AB (publ) designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CALT?

Mr. Mikael Widell
Head of Communications & IR
Mr. Jonathan A. Schur
Group Gen. Counsel
Ms. Sandra Frithiof
Head of HR
Ms. Teona Johnson
Head of US Marketing
Ms. Renee Aguiar-Lucander
Chief Executive Officer
Dr. Katayoun Welin-Berger Ph.D.
Vice President of Operations
Dr. Johan Haggblad Ph.D.
Chief Scientific Officer
Mr. Andrew B. Udell B.Sc., M.B.A.
Pres of North America Commercial
Dr. Richard S. Philipson M.D.
Chief Medical Officer
Dr. Krassimir Mitchev
Head of Medical Affairs
Mr. Fredrik Johansson
Chief Financial Officer
Ms. Ann-Kristin Myde BSc
Head of Clinical Devel. & Vice President of Project Management

How CALT did perform over past 52-week?

CALT's closing price is 162.3% higher than its 52-week low of $15.25 where as its distance from 52-week high of $43.00 is -6.98%.

How many employees does CALT have?

Number of CALT employees currently stands at 222.

Link for CALT official website?

Official Website of CALT is: https://www.calliditas.se

How do I contact CALT?

CALT could be contacted at phone 468 411 3005 and can also be accessed through its website. CALT operates from Kungsbron 1, D5, Stockholm, 111 22, Sweden.

How many shares of CALT are traded daily?

CALT stock volume for the day was 9.8K shares. The average number of CALT shares traded daily for last 3 months was 7.73K.

What is the market cap of CALT currently?

The market value of CALT currently stands at $2.15B with its latest stock price at $40.00 and 53.69M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

40.04

Prev. Close

2.15B

Market Cap

Day Low

-22.727329545454545

P/E Ratio

-1.76

EPS (TTM)

-8.1

Cash Flow per Share

Open

53.69M

Number of Shares

Day High

2.5%

Free Float in %

6.24

Book Value

9.8K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 27, 2024	40.00	40.00	40.00	40.00	0
Sep 26, 2024	40.00	40.00	40.00	40.00	0
Sep 25, 2024	40.00	40.00	40.00	40.00	0
Sep 24, 2024	40.00	40.00	40.00	40.00	0
Sep 23, 2024	40.00	40.00	40.00	40.00	0
Sep 20, 2024	40.00	43.00	40.00	40.00	9.8K
Sep 19, 2024	40.40	40.55	40.07	40.16	5.1K
Sep 18, 2024	40.46	40.80	39.20	40.03	6.04K
Sep 17, 2024	40.34	40.34	39.99	39.99	1K
Sep 16, 2024	40.37	40.75	40.00	40.75	3.1K
Sep 13, 2024	39.90	40.30	39.04	40.00	4.32K
Sep 12, 2024	39.80	39.80	39.80	39.80	600
Sep 11, 2024	39.81	40.28	39.80	39.80	3.4K
Sep 10, 2024	39.79	40.07	39.78	39.78	1.34K
Sep 09, 2024	40.12	40.28	39.71	39.78	10.61K
Sep 06, 2024	40.00	41.31	40.00	40.75	22.7K
Sep 05, 2024	40.45	40.50	39.68	40.28	9.71K
Sep 04, 2024	41.14	41.50	39.71	40.45	18.13K
Sep 03, 2024	40.32	42.10	40.11	41.55	11.81K
Aug 30, 2024	40.12	40.14	39.69	40.12	4.42K

Contact Details

Stockholm, 111 22

Sweden

https://www.calliditas.se 468 411 3005

About Company

Stock Peers

ARGX

-4.96-0.57%

argenx SE$857.97 REGN

14.49+2.18%

Regeneron Pharmaceuticals, Inc.$678.94 MDGL

-4.72-0.86%

Madrigal Pharmaceuticals, Inc.$545.53 UTHR

-2.74-0.52%

United Therapeutics Corporation$529.05 VRTX

8.95+1.88%

Vertex Pharmaceuticals Incorporated$486.03 KRYS

-8.45-2.41%

Krystal Biotech, Inc.$341.79 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

6.16+1.98%

BeOne Medicines AG$317.42 PRAX

-10.22-3.21%

Praxis Precision Medicines, Inc.$308.20 LGND

0.19+0.06%

Ligand Pharmaceuticals Incorporated$296.45

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Shareholding & Insider Activity

Calliditas Therapeutics AB (publ) has 27.02 million shares outstanding. The public float is 676.75 thousand shares, elevated short interest at 0.02% of float. This equals 3.49 thousand shares. The short ratio is 0.3 days.

Financial & Profitability Overview

Over the trailing twelve months, Calliditas Therapeutics AB (publ) generated $1.21B in revenue, or $22.49 per share. Gross margin was 93.62%, operating margin -31.85%, and net profit margin -38.63%. Returns are negative, with ROA at -25.07% and ROE at -139.24%.
On valuation metrics, Calliditas Therapeutics AB (publ) trades at a P/E of -22.22, P/S of 17.18 and P/B of 30.95. The current ratio is 3.13 and quick ratio is 3.08. Operationally, the company’s inventory turnover is 3.77 and cash conversion cycle is -322.67 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 2.92, supported by a cash flow-to-debt ratio of -0.44.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Calliditas Therapeutics AB (publ) posted revenue of $1.21B, down slightly from $802.88M in the prior quarter. Gross profit was $1.13B (margin 93.62%). Operating income was - $384.40M (margin -31.9%). Net income was- $466.19M (EPS - $8.69).
The company ended the quarter with $973.73M in cash and short-term investments, a total debt of $966.60M, and net debt of - $7.14M. Total assets were $1.86B, with equity of $334.81M. Financials further reflected weakness, with operating cash flow of - $434.66M, free cash flow of - $434.66M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Calliditas Therapeutics AB (publ) stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.15%, with price expected at $39.94 by October 11, 2024, within a range of $39.41 to $40.43 3-Month Outlook: Projected fall of -37.6%, reaching $24.96 by December 19, 2024, with a range of $19.23 to $27.54. 1-Year Outlook: Projected gain of 19.88%, with price at $47.95 by September 19, 2025, within a range of $46.01 to $50.26.

Key Takeaways

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) shares are up 55.38% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Calliditas Therapeutics AB (publ) trading at a premium to the broader market with a P/E of -22.22. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $43.75, suggesting 9.38% upside. Our AI forecast model points to short-term weakness (-0.15% over two weeks), a medium-term fall (-37.6% over three months), and a longer-term gain (19.88% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Calliditas Therapeutics AB (publ) (CALT) stock price?

CALT's industry and sector of operation?

Who are the executives of CALT?

How CALT did perform over past 52-week?

CALT's closing price is 162.3% higher than its 52-week low of $15.25 where as its distance from 52-week high of $43.00 is -6.98%.

How many employees does CALT have?

Number of CALT employees currently stands at 222.

Link for CALT official website?

Official Website of CALT is: https://www.calliditas.se

How do I contact CALT?

CALT could be contacted at phone 468 411 3005 and can also be accessed through its website. CALT operates from Kungsbron 1, D5, Stockholm, 111 22, Sweden.

How many shares of CALT are traded daily?

CALT stock volume for the day was 9.8K shares. The average number of CALT shares traded daily for last 3 months was 7.73K.

What is the market cap of CALT currently?

The market value of CALT currently stands at $2.15B with its latest stock price at $40.00 and 53.69M of its shares outstanding.

Employees	222
Beta	1.46
Sales or Revenue	$1.21B
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CALT Company Profile and Key Details

Calliditas Therapeutics AB (publ)

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights